LeukoVantage, Myeloproliferative Neoplasms (MPN)
Also known as: Myeloid NGS Panel MPN
Use
LeukoVantage Myeloproliferative Neoplasms (MPN) panel detects mutations in genes associated with MPN to assist in diagnosis, subclassification, and prognosis of BCR‑ABL1‑negative MPNs. It includes detection of primary driver mutations (e.g., JAK2, CALR, MPL) and secondary drivers (e.g., ASXL1, EZH2, TET2), supporting diagnosis when standard genetic markers are absent and informing risk stratification and subclassification.
Special Instructions
Insurance authorization is required prior to draw for outpatients; not required for inpatients. Requisition form and pathology/flow cytometry reports are required. Only extracted DNA from appropriately qualified laboratories (CLIA‑certified or equivalent to CAP/CMS) is accepted.
Limitations
This NGS panel detects only SNVs and small insertions/deletions (INDELs) at allele frequency ≥5%, with insertion detection limited to 33 bp and deletions up to 52 bp; variants outside these limits may be reported at the medical director’s discretion. Synonymous variants, benign polymorphisms, promoter/intronic variants (except splice‑site), and normal population variants are excluded. A negative result does not rule out MPN.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2‑5 mL
Minimum Volume
2 mL
Container
Lavender (EDTA) tube
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Room Temp: 14 Days |
| Refrigerated | Refrigerated: 14 Days |
| Frozen | Frozen: Unacceptable |